SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private in 2017, has released its 2022 interim report. The company generated RMB 1.475 billion ($204.2 million) in revenues during the first half of this year, up 10.8% year-on-year (YOY). Operating profits grew by 8.4% YOY to RMB 1.134 billion ($157 million), and operating cash flow increased by 69.9% YOY to RMB 524 million ($72.5 million).
Product Sales and Development
During the period, Zadaxin (thymalfasin), the company’s hepatitis B virus (HBV) therapy under development to prevent and treat COVID-19, achieved sales of RMB 1.179 billion ($163.2 million), up 7% YOY. Licensed products saw a significant increase in sales, up 130%, primarily driven by zoledronic acid and the pilot application of Danyelza (naxitamab), a GD2-targeted monoclonal antibody (mAb), in Boao Lecheng and the Tianjin free trade zone.
Marketing Platform and Pipeline
SciClone has been ramping up its Go-To-Patient (GTP) marketing platform, which accounted for 72% of total sales in the first half of 2022. The platform has seen steady growth, accounting for 20%, 30%, 50%, 60%, and 72% of total sales in 2018, 2019, 2020, 2021, and the first half of 2022, respectively. A total of 153,000 patients and 109,000 physicians have subscribed to the offering, which includes 800 Direct to Patient (DTP) pharmacies.
Future Outlook and Drug Candidates
SciClone has nine drug candidates under development, with five at Phase III and later stages abroad, and four at early stages ranging from pre-clinical to Phase II. Among them, Biologic License Applications (BLAs) for Danyelza and Omburtamab, a CNS/neuroblastoma therapy, are expected to be approved in China and the US, respectively, within this year.-Fineline Info & Tech
